Training Activity References:
Heroin-related noncardiogenic pulmonary edema: a case series. Chest. 2001; 120: 1628-1632.
In 12-step groups, helping helps the helper. Addiction. 2004; 99(8): 1015-23.
Substance Abuse in Brief Fact Sheet DHHS Publication No. (SMA) 06-4187. DHHS. 2006; (4)2: .
A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR. 2005; 54(RR-16): 1-39.
A comprehensive review of the psychometric properties of the drug abuse screening test. Journal of Substance Abuse Treatment. 2007; 32(2): 189-198.
A Guide to Substance Abuse Services for Primary Care Clinicians. Rockville, Md: Center For Substance Abuse Treatment. Treatment Improvement Protocol Series, No. 24. USDHHS Publication (SMA) 97-3139. 1997.
A psychometric study of the prevalence of DSM-IV personality disorders among office-based methadone maintenance patients. The American Journal of Drug and Alcohol Abuse. 2004; 30(3): 515-524.
A randomized controlled trial of intensive referral to 12-step self-help groups: one-year outcomes. Drug and Alcohol Dependence. 2007; 90(2): 270-279.
A risk-benefit analysis of methadone maintenance treatment. In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, eds. Principles of Addiction Medicine. 3rd ed. Chevy Chase, Md: American Society of Addiction Medicine. 2003.
A two-item conjoint screen for alcohol and other drug problems. J Am Board Fam Pract. 2001; 14(2): 95-106.
Accessing opiate dependence treatment medications: buprenorphine products in an office-based setting. Drug Alcohol Depend. . 2003; 70(2 Suppl): S103-4.
Adherence to pharmacotherapy in patients with alcohol and opioid dependence. Addiction. 2004; 1382-1392: .
Adolescent substance abuse. Confidentiality and consent. The Pediatric Clinics of North America. 2002; 49(2): 301-315.
Adolescents with co-occurring mental health and substance use disorders in primary care. Adolescent Medical Clinics. 2006; 17(2): 427-452.
Advances in diagnosis of adolescent substance abuse. Adolescent Medical Clinics. 2006; 17(2): 411-425.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed, Text Revision. Washington, DC. American Psychiatric Association. 2000.
Anxiety disorders, comorbid substance abuse, and benzodiazepine discontinuation: implications for treatment. NIDA Res Monogr. 1997; 172: 33-51.
Assessment and treatment of comorbid psychiatric disorders in opioid-dependent patients. The Clinical Journal of Pain. 2002; 18(4): 14-26.
Balancing confidentiality and the information provided to families of patients in primary care. Journal of Medical Ethics. 2005; 31(9): 531-535.
Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sciences. 2005; 76(13): 1427-1437.
Bipolar disorder and substance abuse. Journal of Biological Psychiatry. 2004; 56: 738-748.
Borg L, Kreek MJ. The pharmacology of opioids. In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB. Principles of Addiction Medicine. 3rd ed. Chevy Chase, Md: American Society of Addiction Medicine. 2003.
Borg L, Kreek MJ. The pharmacology of opioids. In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB. Principles of Addiction Medicine. 3rd ed. Chevy Chase, Md: American Society of Addiction Medicine. 2003.
Brief substance use screening instruments for primary care settings: a review. Journal of Substance Abuse Treatment. 2000; 18(2): 193-202.
Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug and Alcohol Dependence. 2000; 61(1): 85-94.
Buprenorphine/naloxone treatment in primary care is associated with decreased human immunodeficiency virus risk behaviors. Journal of Substance Abuse Treatment. 2008; 35(1): 87-92.
Buprenorphine: Considerations for Pain Management. Journal of Pain and Symptom Management. 2005; 29(3): 297-326.
Buprenorphine: field trials of a new drug. Qual Health Res. 2001; 11(1): 69-84.
Buprenorphine: how to use it right. Drug Alcohol Depend. 2003; 70(suppl 2): S59-S77.
Characteristics of older opioid maintenance patients. J Subst Abuse Treat. 2005; 28(3): 265-72.
Characteristics of older opioid maintenance patients. Journal of Substance Abuse Treatment. 2005; 28(3): 265-272.
Clinic-based treatment for opioid dependence: a qualitative inquiry. American Journal of Health Behavior. 2006; 30(5): 544-554.
Co-occurrence of personality disorders with mood, anxiety, and substance use disorders in a young adult population. Journal of Personality Disorders. 2006; 20(1): 102-112.
Co-occurring psychiatric disorders in women with addictions. Obstetrics and Gynecology Clinics of North America. 2003; 2003: 469-481.
College on Problems of Drug Dependence Taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 2003; 69(3): 215-232.
Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and interferon-based therapy complications. Journal of Psychiatric Practice. 2003; 9(2): 93-110.
Conceptualizing and assessing treatment structure and process in community-based drug dependency treatment programs. Substance Use Misuse . 2000; 35(12-14): 1757-1795.
Concerns over confidentiality may deter adolescents from consulting their doctors. A qualitative exploration. Journal of Medical Ethics. 2006; 32(3): 133-137.
Consent to treatment and confidentiality provisions affecting minors in Pennsylvania. 2nd edition. Philadelphia: Juvenile Law Center. 2006.
Constitutive Activity and Inverse Agonists of G Protein-Coupled Receptors: a Current Perspective. Molecular Pharmacology. 2003; 64(6): 1271-1276.
Definitions related to the use of opioids for the treatment of pain. Available at: http://www.painmed.org/pdf/definition.pdf. 2001. Accessed on: 2008-04-14.
Delivery of HIV risk-reduction services in drug treatment programs. J Subst Abuse Treat. 2000; 19(3): 229-237.
Developments in the treatment of drug dependence. Curr Opin Psychiatry. . 2000 ; 13(3): 333-338.
Diagnosis of comorbid psychiatric disorders in substance users assessed with the psychiatric research interview for substance and mental disorders for DSM-IV. American Journal of Psychiatry. 2006; 193: 689-696.
Dilemmas in diagnosing and treating co-occurring disorders. Behavioral Healthcare Tomorrow. 2004; 13(4): 42-47.
Drug Abuse Warning Network, 2005: National Estimates of Drug-Related Emergency Department Visits. DAWN Series D-29. DHHS Publication No. (SMA) 07-4256. Rockville, MD. 2007.
Dual diagnosis: substance-related and psychiatric disorders. The Nursing Clinics of North America. 2003; 38: 67-73.
Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans. Psychopharmacology (Berl). 2002; 160(4): 344-52.
Exercise activates the endocannibinoid system. NeuroReport. 2003; 14(17): 2209-2211.
Family interventions for drug and alcohol misuse: is there a best practice?. Curr Opin Psychiatry. 2006; 19(3): 271-6.
Foundations of Opioid Risk Management. Clinical Journal of Pain. 2007; 23(2): 103-118.
GABAergic mechanisms of opiate reinforcement. Alcohol & Alcoholism. 2002; 37(5): 485-494.
Gitlow S. Substance Use Disorders. Philadelphia, Pa: Lippincott Williams & Wilkins. 2006.
Harrison L. The validity of self-reported drug use in survey research: an overview and critique of research methods. In: Harrison L, Hughes A, eds. The Validity of Self-Reported Drug Use: Improving the Accuracy of Survey Estimates. Rockville, Md: National Institute on Drug Abuse; 1997:17-36. Publication 97-4147, NIDA Research Monograph 167. 1997.
Helping 'them': our role in recovery from opioid dependence. Annals of Family Medicine. 2006; 4(2): 168-171.
Hepatitis B virus infection and vaccination among young injection and non-injection drug users: missed opportunities to prevent infection. Drug and Alcohol Dependence. 2004; 73(1): 69-78.
Hepatitis C and HIV risk behaviors in polydrug users on methadone maintenance. J Subst Abuse Treat. 2008; 35(1): 78-86.
Hepatitis C virus infection and substance abuse. Clinical Infectious Diseases. 2005; 40: 259-262.
HIV Diagnoses Among Injection-Drug Users in States with HIV Surveillance --- 25 States, 1994--2000. MMWR. 2003; 52(27): 634-636.
HIV/AIDS Among Women. Fact Sheet. 2008.
How much can treatment reduce national drug problems?. Addiction. 2006; 101(3): 341-347.
Illicit use of opioid analgesics by high school seniors. Journal of Substance Abuse Treatment. 2005; 28(3): 225-230.
Informed consent to undergo treatment for substance abuse: a recommended approach. Journal of Substance Abuse Treatment. 2005; 29(4): 241-251.
Kleber HD, Weiss RD, Anton RF, Rounsaville BJ, George TP, Strain EC, Greenfield SF, Ziedonis DM, Kosten TR, Hennessy G, O'Brien CP, Connery HS, McIntrye JS, Charles SC, Anzia DJ, Nininger JE, Cook IA, Summergrad P, Finnerty MT, Woods SM, Johnson BR, Yager J, Pyles R, Lurie L, Cross CD, Walker RD, Peele R, Barnovitz MA, Gray SH, Shemo JP, Saxena S, Tonnu T, Kunkle R, Albert AB, Fochtmann LJ, Hart C, Regier D. Practice guideline for the treatment of patients with substance use disorders, 2nd edition. Am J Psychiatry. 2006; 163(8 Suppl): 5-82.
Kreek MJ. Opiate Antagonist Treatment, Molecular Pharmacology, and Physiology. Presentation at the Consensus Conference on Effective Medical Treatment of Heroin Addiction. Bethesda, Md: National Institutes of Health. 1997.
Management of opioid dependence. Current Opinion in Psychiatry. 2003; 16(3): 297-304.
Maremmani I, Pani PP, Mellini A, Pacini M, et al. Alcohol and cocaine use and abuse among opioid addicts engaged in a methadone maintenance treatment program. J Addict Dis. 2007; 26(1): 61-70.
Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Systematic Reviews. CD002207. 2002.
Medical illness and comorbidities in drug users: implications for addiction pharmacotherapy treatment. Substance Use and Misuse. 2005; 40(13-14): 1899-1921.
Medication development for addictive disorders: the state of the science. American Journal of Psychiatry. 2005; 162(8): 1432-40.
Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Rockville, MD: Substance Abuse and Mental Health Services Administration. Treatment Improvement Protocol (TIP) Series 43. DHHS Publication No. (SMA) 05-4048. 2005.
Medications development: successes and challenges. Pharmacology & Therapeutics. 2005; 108(1): 94-108.
Metabolic consequences of drug misuse. Br J Anaesth. 2000; 85(1): 136-142.
Naloxone reversal of buprenorphine-induced respiratory depression. Anesthesiology. 2006; 105(1): 51-57.
National Drug Intelligence Center. Information Bulletin January 2001: OxyContin Diversion and Abuse. Johnstown, Pa: National Drug Intelligence Center. Product 2001-L0424-001. 2001.
National Institute on Drug Abuse. Principles of Drug Addiction Treatment: A Research-Based Guide. Rockville, Md: National Institute on Drug Abuse. 1999.
Network Therapy for addiction: assessment of the clinical outcome of training. Am J Drug Alcohol Abuse. 1997; 23(3): 355-67.
Network therapy: decreased secondary opioid use during buprenorphine maintenance. J Subst Abuse Treat. 2004; 26(4): 313-8.
Neural systems underlying opiate addiction. J Neurosci. 2002; 22(9): 3321-3325.
O'Brien CP, Cornish JW. Opioids: antagonists and partial agonists. In: Galanter M, Kleber HD, eds. Textbook of Substance Abuse Treatment. 2nd ed. Washington, DC: American Psychiatric Press, Inc. 1999.
Office of National Drug Control Policy. What America’s Users Spend on Illegal Drugs, 1988–2000. Office of National Drug Control Policy. 2001.
Office-based practice and opioid-use disorders. New England Journal of Medicine. 2004; 349(10): 928-930.
Office-based treatment of opioid-dependent patients. American Family Physician. New England Journal of Medicine. 2002; 347(11): 817-822.
Opioid Abuse. JAMA. 2004; 291(11): 1394.
Opioid Analgesia. New York: McGraw Hill. 2004.
Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments. Clinical Infectious Diseases. 2006; 43: S173-177.
Opioid maintenance: a comparative review of pharmacological strategies. Expert Opinion on Pharmacotherapy. 2007; 8(1): 1-11.
Opioid prescriptions soar: increase in legitimate use as well as abuse. Journal of the American Medical Association. 2007; 297(3): 249-251.
Outcome and impact of mental disorder in primary care at 5 years. Pychosomatic Medicine. 2007; 69(3): 270-276.
Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clinical Infectious Diseases. 2005; 40(S5): 276-285.
Parental substance use disorder and the risk of adolescent drug abuse: an event history analysis. Drug and Alcohol Dependence. 2002; 66(3): 255-264.
Patient assessment and selection for buprenorphine treatment. Addiction Professional. 2005; 2:17: .
Patient characteristics and risk factors for development of dependence on hydrocodone and oxycodone. American Journal of Therapeutics. 2004; 11(1): 26-32.
Patient-doctor communication. Medical Clinics of North America. 2003; 87(5): 1115-45.
Patients with pain and addiction: what's a doctor to do?. Minnesota Medicine. . 2006; 89(9): 41-43.
Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003; 70(suppl 2): S39-S47.
Pharmacologic treatment of heroin-dependent patients. Ann Intern Med. 2000; 133(1): 40-54.
Pharmacotherapy of Comorbid Mood, Anxiety, and Substance Use Disorders. Substance Use and Misuse. 2005; 40: 2021-2041.
Physicians advised on how to offer pain relief while preventing opioid abuse. Journal of the American Medical Association. 2004; 292(4): 1164-1166.
Physicians-in-training attitudes toward caring for and working with paitents with alcohol and drug abuse diagnoses. South Med J. 2006; 99: 28-35.
Potential for abuse of buprenorphine in office-based treatment of opioid dependence (letter). New England Journal of Medicine. 2005; 353(17): 1863-1865.
Practice guideline for the treatment of patients with substance use disorders, 2nd edition. Am J Psychiatry. 2006; 163(8): 5-82.
Prescription Drugs: OxyContin Abuse and Diversion and Efforts to Address the Problem. Report to Congressional Requesters. 2003.
Prevalence and characteristics of clients with co-occurring disorders in outpatient substance abuse treatment. The American Journal of Drug and Alcohol Abuse.. 2004; 20(4): 749-764.
Prevalence and co-occurrence of substance disorders and independent mood and anxiety disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Archives of General Psychiatry. 2004; 61(8): 807-816.
Prevalence of psychiatric and substance use disorders in opioid abusers in a community syringe exchange program. Drug and Alcohol Dependence. 2004; 74-2: 115-122.
Professional satisfaction experienced when caring for substance-abusing patients . Journal of General Internal Medicine. 2002; 17(5): 1525-1597.
Psychoactive drug abuse in older adults. The American Journal of Geriatric Pharmacotherapy. 2006; 4(4): 380-394.
Pulmonary effects of illicit drug use. Clinics in Chest Medicine. 2004; 25: 203-216.
Pulse Check: Trends in Drug Abuse, January - June 2002 Reporting Period. Publication NCJ-197242. 2002.
Recent trends in adolescent substance use, primary care screening, and updates in treatment options. Curr Op in Pediatr. 2006; 18(4): 352-8.
Recognition of alcohol and substance abuse. American Family Physician. 2003; 67(7): 1529-1532,1535-1536.
Report of the CSAT National Advisory Council (NAC) subcommittee on oral fluid testing. USDHHS. 2003b.
Research Report Series: Heroin Abuse and Addiction. Rockville, MD: US Dept of Health and Human Services. 2005.
Retention in publicly funded methadone maintenance treatment in two western states.. J Behav Health Serv Res. 2005; 32(1): 43-60.
Role of the primary care physician in problems of substance abuse. Archives of Internal Medicine. 1999; 159(9): 913-924.
SAMHSA/CSAT Evaluation of the buprenorphine waiver program. Paper presented at: 37th Annual Medical- Scientific Conference of the American Society of Addiction Medicine. 2006.
Screening for serious mental illness in populations with co-occurring substance use disorders: performance of the K6 scale. Journal of Substance Abuse Treatment. 2006; 31: 287-296.
Screening for serious mental illness in populations with co-occurring substance use disorders: performance of the K6 scale. Journal of Substance Abuse Treatment.. 2006; 31: 287-296.
Senay EC. Opioids: methadone maintenance. In: Galanter M, Kleber HD, eds. Textbook of Substance Abuse Treatment. 2nd ed. Washington, DC: American Psychiatric Press, Inc. 1999.
Shea SC. The Practical Art of Suicide Assessment. New York, NY: John Wiley. 1999.
Shift seen in patterns of drug use among teens. Journal of the American Medical Association. 2006; 295(6): 612-613.
Should patients' religiosity influence clinicians' referral to 12-step self-help groups? Evidence from a study of 3,018 male substance abuse patients. J Consult Clin Psychol. 1999; 67(5): 790-794.
Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction. 1998; 93(9): 1385-92.
Stenbacka M, Beck O, Leifman A, Romelsjo A, Helander A. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment. Drug and Alcohol Review. 2007; 26(1): 55-63.
Stephens RC. The Street Addict Role: A Theory of Heroin Addiction. Albany: State University of New York Press. 1991.
Substance Abuse and Mental Health Services Administration, Center for Substance Abuse Treatment. A Guide to Substance Abuse Services for Primary Care Clinicians. Rockville, Md: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration. Treatment Improvement Protocol Series, No. 24. Publication (SMA) 02-3687. 1997.
Substance Abuse and Mental Health Services Administration. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Rockville, Md: Center For Substance Abuse Treatment. Treatment Improvement Protocol Series, No. 40, USDHHS Publication (SMA) 04-3939.
2004. Available at: http://www.ncbi.nlm.nih.gov/books/NBK64766/
Accessed on: 2011-12-12.
Substance Abuse and Mental Health Services Administration. Overview of Findings From the 2002 National Survey on Drug Use and Health. Rockville, Md: Office of Applied Studies. NHSDA Series H-21. USDHHS Publication SMA 03-3774. 2003.
Substance Abuse and Mental Health Services Administration. Preliminary Results From the 1996 National Household Survey on Drug Abuse. Rockville, Md: US Dept of Health and Human Services. 1997.
Substance abuse treatment for persons with co-occurring disorders. Treatment Improvement Protocol (TIP) Series. DHHS Publication No. (SMA) 05-3922.
2005. Available at: http://www.ncbi.nlm.nih.gov/books/NBK64197/
Accessed on: 2010-06-15.
Substance abuse treatment providers' referral to self-help: review and future empirical directions. Int J Self Help Self Care. 2000; 1(3): 213-225.
Suicide prevention plan calls for physicians' help. JAMA. 2001; 285(21): 2701-2703.
The Addiction behaviors checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain. Journal of Pain and Symptom Management. 2006; 32(4): 342-351.
The availability of web sites offering to sell opioid medications without prescriptions. Am J Psychiatry. 2006; 8(5): 377-8.
The Clinical Opiate Withdrawal Scale (COWS). Journal of Psychoactive Drugs. 2003; 35(2): 253-259.
The development of a comprehensive risk-management program for prescription opiod analgesics: researched abuse, diversion, and addiction-related surveillance (RADARS). Pain Medicine. 2007; 2(8): 157-170.
The health insurance portability and accountability act (HIPAA): its broad effect on practice. American Journal of Gastroenterology. 2005; 100: 1440-1443.
The heroin epidemic in New York City: current status and prognoses. J Psychoactive Drugs. 1997; 29(4): 375-391.
The initiation of the use of heroin in the age of crack-cocaine. In: Inciardi JA, Harrison LD, eds. Heroin in the Age of Crack-Cocaine. Thousand Oaks, Calif: SAGE Publications, Inc. 1998.
The medical complications of heroin use. Current Opinion in Psychiatry. 2005; 18(3): 257-263.
The neurobiology of opioid addiction: implications for treatment. NIDA Science and Practice Perspectives. 2002; 1(1): 13-20.
The reality of comorbidity: depression and drug abuse. Biological Psychiatry. 2004; 56: 714-717.
The right of minors to confidentiality and informed consent. Journal of Child Neurology. 2004; 19(2): 145-148.
Treating opioid dependence. Archives of Internal Medicine. 2004; 164(3): 277-288.
Treatment Episode Data Set (TEDS): 1994-2004. National Admissions to Substance Abuse Treatment Services. DASIS Series: S-33, DHHS Publication No. (SMA) 06-4180. Rockville, MD. 2006b.
Treatment of depression in patients with opiate dependence. Biological Psychiatry. 2004; 56: 793-802.
Treatment structure and program services in the drug abuse treatment outcome study (DATOS). Psychology of Addictive Behaviors. 1997; 11(4): 244-260.
Understanding polydrug use: review of heroin and cocaine co-use. Addiction. 2003; 98: 7-22.
Unifying perspective of the mechanisms underlying the development of tolerance and physical dependence to opioids. J Pharmacol Exp Ther. 2001; 297(1): 11-18.
Use of Buprenorphine in the Pharmacologic Management of Opioid Dependence: A Curriculum for Physicians. Substance Abuse and Mental Health Services Administration. 2001.
Use of standardized patients in undergraduate medical genetics education. Teach Learn Med. 2006; 18(3): 203-7.
When you suspect a drug problem. Minnesota Medicine. 2006; 89: .
Why physicians are unprepared to treat patients who have alcohol- and drug-related disorders. Academic Medicine. 2001; 76(5): 410-418.